CureVac BV

CureVac is a biopharmaceutical company headquartered in Tübingen, Germany, that develops treatments based on matrix RNAi (mRNA).
CureVac BV stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

CureVac BV balance sheet

Report period2019 2020 2021 2022 2023 Q1 24
End date of the reporting period
Capitalization, €
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

CureVac BV cash flows

Report period2019 2020 2021 2022 2023 Q1 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

CureVac BV multipliers

Report period2019 2020 2021 2022 2023 Q1 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

CureVac BV profitability

Report period2019 2020 2021 2022 2023 Q1 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
CureVac BV assets
CureVac BV cash flows

CureVac BV shares

TickerNameTypeNominal valueISINPrice
CVAC:USCureVac BVCommon share-NL0015436031$3.31
CureVac BV news
29.04.2022
CureVac's IFRS loss for 2021 was €411.716 million, up 3.2 times from €129.122 million in the previous year. Revenue increased 2.2 times to €102.99 million compared to €48.871 million a year earlier.
Source: {source} pictogram sec.gov
Pictogram next
19.11.2021
CureVac's IFRS pre-tax loss for 9M 2021 was €143.5 million, a 3.9-fold increase from €36.7 million in the previous year. Revenue increased 5.6-fold to €29.3 million compared to €5.2 million a year earlier.
Source: {source} pictogram curevac.com
Pictogram next
17.06.2021
The efficacy of CureVac's coronavirus vaccine, based on the results of the main phase of the trial, is 47%. The results did not meet predetermined criteria for statistical success.
Source: {source} pictogram curevac.com
Pictogram next
27.04.2021
CureVac BV' IFRS loss for 2020 was €129.122 million, an increase of 29.3% compared to €99.873 million in the previous year. Revenue increased 2.8 times to €48.871 million compared to €17.416 million a year earlier.
Source: {source} pictogram curevac.gcs-web.com
Pictogram next
All CureVac BV news
General information
Company nameCureVac BV
Business addressPAUL-EHRLICH-STRABE 15 TUBINGEN BADEN-WURTTEMBERG 2M 72076 49 7071 9883 0
Mailing addressPAUL-EHRLICH-STRABE 15 TUBINGEN BADEN-WURTTEMBERG 2M 72076
Websitewww.curevac.com
Information disclosurewww.sec.gov